Get access

Progression of premanifest and early Huntington's disease detectable after 1 year—Does TRACK-HD open the door to disease-modifying trials in HD and beyond?

Authors

  • Ralf Reilmann MD

    1. Chair EHDN Huntington Center Münster & EHDN Neuroprotective, Therapy Working Group, Department of Neurology, University Clinic Muenster (UKM), Westfaelische-Wilhelms University of Muenster, Muenster, Germany
    Search for more papers by this author

  • Relevant conflicts of interest/financial disclosures: Nothing to report.

No abstract is available for this article.

Ancillary